Information Provided By: 
Fly News Breaks for March 23, 2017
JAZZ
Mar 23, 2017 | 09:11 EDT
Wells Fargo analyst David Maris said the USPTO's finding that three claims of Jazz Pharmaceuticals' patent covering Xyrem's specialized distribution system are unpatentable is incrementally negative, but added that he would not be surprised if the company appeals to the Federal Circuit. He added that it typically takes 12-18 months for a Federal Circuit final decision. Maris, who notes other litigation regarding Xyrem's patents and continues to see potential for a settlement, keeps an Outperform rating on Jazz shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
